New drug aims to tame uncontrollable hives
NCT ID NCT06365879
Summary
This study is testing a new version of a drug called omalizumab (CMAB007) for people with chronic hives that don't respond to standard allergy pills. It will compare this new version directly to the already-approved drug Xolair to see if they work the same. About 392 participants will receive injections every four weeks for 12 weeks, followed by an 8-week safety check.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.